Brink A A, ten Berge R L, van den Brule A J, Willemze R, Chott A, Meijer C J
Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
J Pathol. 2000 Aug;191(4):400-6. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH658>3.0.CO;2-G.
Epstein-Barr virus (EBV)-positive T non-Hodgkin lymphomas (T-NHLs) have been described, but it is at present unknown how EBV infects T lymphocytes. It has been postulated that cytotoxic T cells (CTLs) or natural killer (NK) cells can be infected by EBV during the killing of an EBV-infected target cell. The objective of this study was therefore to determine whether the neoplastic cells in EBV-positive T-NHLs (n=221) of various locations have a cytotoxic phenotype. To identify EBV-harbouring cells, combinations were used of EBV-encoded RNA (EBER) in situ hybridization (RISH) and immunohistochemistry for T- and B-cell markers and the cytotoxic proteins TIA-1 and granzyme B. EBV was detected in the neoplastic cells of all nasal T-NHLs (n=9), 5/34 gastrointestinal (GI) T-NHLs, and 2/6 lung T-NHLs, but not in primary cutaneous T-NHLs (n=103). Moreover, EBV was found in the neoplastic cells of 2/48 nodal anaplastic large cell lymphomas (ALCLs), but not in neoplastic T cells of other nodal T-NHLs. However, 5/17 nodal peripheral T-NHLs not otherwise specified (PTCLs NOS) and 1/4 T-prolymphocytic leukaemias did contain EBV-positive non-T cells. Double staining revealed that in EBV-positive extranodal T-NHLs (n=16), the EBER-positive cells had a cytotoxic phenotype (TIA-1- and/or granzyme B-positive). In nodal non-ALCL T-NHLs, the EBER-positive cells were not positive for TIA-1 or granzyme B, nor did they express CD3, CD21 or HECA452. Instead, most of these cells expressed the B-cell marker CD20. These PTCLs NOS with EBER-positive cells showed features of AILD-like T-NHL. It is concluded that neoplastic cells of EBV-positive extranodal T-NHLs always have a cytotoxic phenotype, supporting the view that EBV can infect CTLs. In nodal non-ALCL T-NHL, EBV is only found in T-NHL with AILD-like features and is present in B cells, where it may contribute to the outgrowth of a malignant B-cell clone.
已有关于爱泼斯坦-巴尔病毒(EBV)阳性T细胞非霍奇金淋巴瘤(T-NHL)的报道,但目前尚不清楚EBV如何感染T淋巴细胞。据推测,细胞毒性T细胞(CTL)或自然杀伤(NK)细胞在杀伤被EBV感染的靶细胞过程中可能被EBV感染。因此,本研究的目的是确定不同部位的EBV阳性T-NHL(n=221)中的肿瘤细胞是否具有细胞毒性表型。为了识别携带EBV的细胞,联合使用了EBV编码RNA(EBER)原位杂交(RISH)以及针对T细胞和B细胞标志物、细胞毒性蛋白TIA-1和颗粒酶B的免疫组织化学方法。在所有鼻型T-NHL(n=9)、5/34例胃肠道(GI)T-NHL以及2/6例肺T-NHL的肿瘤细胞中检测到EBV,但在原发性皮肤T-NHL(n=103)中未检测到。此外,在2/48例淋巴结间变性大细胞淋巴瘤(ALCL)的肿瘤细胞中发现了EBV,但在其他淋巴结T-NHL的肿瘤T细胞中未发现。然而,5/17例未另行特指的淋巴结外周T-NHL(PTCLs NOS)和1/4例T-原淋巴细胞白血病确实含有EBV阳性非T细胞。双重染色显示,在EBV阳性结外T-NHL(n=16)中,EBER阳性细胞具有细胞毒性表型(TIA-1和/或颗粒酶B阳性)。在淋巴结非ALCL型T-NHL中,EBER阳性细胞TIA-1或颗粒酶B呈阴性,也不表达CD3、CD21或HECA452。相反,这些细胞中的大多数表达B细胞标志物CD20。这些具有EBER阳性细胞的PTCLs NOS表现出AILD样T-NHL的特征。结论是,EBV阳性结外T-NHL的肿瘤细胞总是具有细胞毒性表型,支持EBV可感染CTL的观点。在淋巴结非ALCL型T-NHL中,EBV仅在具有AILD样特征的T-NHL中发现,且存在于B细胞中,这可能有助于恶性B细胞克隆的生长。